Nivolumab, marketed under the brand name Opdivo, is a monoclonal antibody that works as an immune checkpoint inhibitor. It specifically targets and blocks the programmed death-1 (PD-1) receptor on T cells, allowing the immune system to recognize and destroy cancer cells more effectively.
